Primary biliary cirrhosis is a chronic cholestatic disease of unknown aetiology which affects predominantly middle aged women. It is characterised by many 
Results
In primary biliary cirrhosis the frequencies of the HLA-DR locus antigens were not significantly different from those in the normal controls (see Table  1 ). None of the HLA-A or B antigen frequencies in the patient groups showed any significant differences from the normal controls. No HLA-DR antigen was significantly associated with the two factors which are thought to reflect the prognosis of primary biliary cirrhosis (see Table 2 ). No association with any HLA-DR antigen was found in the 17 patients receiving D-penicillamine who developed drug related adverse effects; in particular none of the four patients who developed significant proteinuria (>2 g/24 hours) were positive for HLA-DR3 antigens. (See Table 3 ).
Discussion
'Autoimmune' diseases may be divided into organspecific and non-organ specific polysystemic disease such as primary biliary cirrhosis. An HLA-DR linkage is now well documented in many organ-specific autoimmune disorders such as those Immunological abnormalities such as mitochrondrial antibodies in the serum may be present in primary biliary cirrhosis for many years without the appearances of overt clinical disease. 6 Although the importance of the presence of granulomas in the liver biopsy, regardless of histological stage, as being indicative of a good prognosis in primary biliary cirrhosis23 has subsequently been challenged,32 the present study provides no support for the hypothesis that, they are associated with any HLA-DR locus. By dividing the patients into those with a raised serum bilirubin and those with a normal or near normal level (Table 2) we have attempted to identify a group with a poor prognosis. Admittedly some of the individuals in whom bilirubin was recorded below 34 Amol/l (2 x normal) may subsequently progress to a higher bilirubin concentration but we feel that the broad division into a group with an acknowledged poor prognosis -those with raised serum bilirubin2l 2 Vs those with a far better prognosis is useful. Again no association between raised serum bilirubin and an HLA-DR antigen has been found. In the present study there is thus no evidence that any gene (or factor) associated with the HLA-DR locus protects against disease progression or conversely is associated with increased susceptibility to severe disease. If primary biliary cirrhosis does result from a failure of the regulatory system of the immune response, its genetic control appears to be localised outside the HLA-DR region, or its allele is in linkage equilibrium with HLA-DR antigens.
Our data are also at variance with a previous report of a trend toward the development of proteinuria during treatment with D-penicillamine in rheumatoid arthritis patients with the HLA-DR W3 locus. Only four of our D-penicillamine treated primary biliary cirrhosis patients developed significant proteinuria and none were HLA-DR3 positive. No significant association was found with any other drug related adverse reaction such as the development of systemic lupus erythematosus. We are thus unable to support the hypotheses that primary biliary cirrhosis disease susceptibility or immunologically mediated drug toxicity in this disorder are controlled by genes in the HLA-DR region of the histocompatibility system. The results provide some evidence against there being an important genetic basis to the disease in most patients.
